

## Optimum Duration and Dose of r-tPA with the Acoustic Pulse Thrombolysis Procedure for Submassive Pulmonary Embolism: OPTALYSE PE

Victor Tapson<sup>1</sup>, Gregory Piazza<sup>2</sup>, Keith Sterling<sup>3</sup>, Kenneth Ouriel<sup>4</sup>, Ping-Yu Liu<sup>5</sup>; Samuel Z. Goldhaber<sup>2</sup> as presented at the American Thoracic Society (ATS) meeting, Washington, DC, May 2017.

### Patients

Acute PE with RV/LV ratio  $\geq 0.9$   
(n= 101; 17 centers)

### Objectives

Evaluate the optimal duration and dose of Acoustic Pulse Thrombolysis™ (APT) treatment using r-tPA administered via the EKOS™ system:

- Efficacy - Change in RV/LV ratio on CTA at 48hrs
- Safety – As measured by major bleeding within 72hrs

### Randomization

| Cohort 1                                    | Cohort 2                                    | Cohort 3                                     | Cohort 4                                      |
|---|---|--|---|
| 26 Patients<br>2 (h) EKOS™<br>4/8 mg r-tPA* | 26 Patients<br>4 (h) EKOS™<br>4/8 mg r-tPA* | 27 Patients<br>6 (h) EKOS™<br>6/12 mg r-tPA* | 18 Patients<br>6 (h) EKOS™<br>12/24 mg r-tPA* |

### Methods

- Anticoagulation therapy using heparin
- Acoustic Pulse Thrombolysis™ treatment using EKOS™ – following duration and dosage of randomly assigned study cohort
- Follow up at 48hrs post treatment start with CTA



1 - Victor Tapson<sup>1</sup> Pulmonary / Critical Care Division, Cedars-Sinai Medical Center, Los Angeles, CA  
2 - Gregory Piazza<sup>2</sup>, Samuel Z. Goldhaber<sup>2</sup> Cardiovascular Division, Brigham and Women's Hospital, Harvard University, Boston MA  
3 - Keith Sterling<sup>3</sup> Cardiovascular & Interventional Radiology, Inova Alexandria Hospital, Alexandria, VA  
4 - Kenneth Ouriel<sup>4</sup> Syntactx, NY, NY  
5 - Ping-Yu Liu<sup>5</sup> Fred Hutchinson Cancer Center, Seattle, WA

\* Total mg r-tPA: one/two catheters





FDA Clearance: The Ekosonic™ Endovascular System is indicated for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified solutions, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries.

CE Mark: The Ekosonic™ Endovascular System is intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. Intended for the treatment of pulmonary embolism patients with  $\geq 50\%$  clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure  $\geq 25$  mmHg) or echocardiographic evaluation.

## Key Results

Acute PE patients treated with EKOS™ showed the following improvements:

- Significant reduction in RV/LV ratios in all cohorts at 48 hours post initiation of procedure.
- RV/LV ratio reduced by 24% (P<0.0001) for the two-hour cohort using only 4mg of r-tPA per catheter.
- All cohorts had zero to very low bleeding rates.<sup>6</sup>



6 - Cohorts 1 and 3 had zero major bleeding incidents, cohort 2 had one incident and cohort 4 had two incidents (including one ICH).

\* Total mg r-tPA: one/two catheters

FDA Clearance: The Ekosonic™ Endovascular System is indicated for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified solutions, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries.

CE Mark: The Ekosonic™ Endovascular System is intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. Intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25 mmHg) or echocardiographic evaluation.

EKOS is a registered trademark of EKOS Corporation, a BTG International group company. 'Imagine where we can go' is a trademark of BTG International, Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in US, EU, and certain other territories and trademarks of BTG International Ltd elsewhere. © 2018 BTG International Ltd.


Imagine where we can go.



## Key Results: Long Term

Patients continued to improve through 365d<sup>7</sup> follow up:

- RV/LV ratio improved significantly across all four cohorts long-term.<sup>7</sup>
- Multiple Quality of Life (QOL) metrics showed valuable improvements from 30d following EKOS™ treatment to 365d post-treatment.
- Very low all-cause mortality and recurrent PE rates of 2% each for all cohorts.





### Long-term OPTALYSE safety & efficacy at 365d

|                          | Mortality | Recurrent PE |
|--------------------------|-----------|--------------|
| OPTALYSE PE              | 2%        | 2%           |
| PEITHO-AC <sup>8</sup>   | 8%        | N/A          |
| PEITHO-TNK <sup>8</sup>  | 10%       | N/A          |
| Baglin - AC <sup>9</sup> | N/A       | 3.7%         |

## Quality of Life

Two unique measurements of quality of life show significant improvements from 30d to 365d following EKOS™ therapy.



7 - Sterling, K. "Long-term Results of the OPTALYSE PE trial" as presented at the International Symposium on Endovascular Therapy (ISET) meeting, Hollywood, FL Feb 2018.  
 8 - Konstantinides, MD, et al, "Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism" Journal of the American College of Cardiology; vol 69, pp.1536-1544, 2017.  
 9 - Baglin, et al., "Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis," Journal of Thrombosis and Haemostasis, vol. 8, no. 11, pp. 2436-2442, 2010. 3.

FDA Clearance: The Ekosonic™ Endovascular System is indicated for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified solutions, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries.

CE Mark: The Ekosonic™ Endovascular System is intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. Intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25 mmHg) or echocardiographic evaluation.

## ACUTE RESULTS:

The EKOS™ system's very low dose and short-duration regimens, in the OPTALYSE PE trial, prove to be as acutely effective as the regimens in previous EKOS™ studies (ULTIMA & SEATTLE II), pointing to a paradigm-changing approach for PE treatment.

## LONG-TERM RESULTS:

The EKOS™ System's very low dose and short duration regimens, in the OPTALYSE PE trial, resulted in rapidly improved measures of right-heart function that were maintained for one year. Additionally, the favorable mortality rates, recurrent PE rates, and quality of life results demonstrate long-term benefits of EKOS™ therapy. This data further proves the PE clinical efficacy and safety of the OPTALYSE PE treatment protocols.

### About EKOS™

EKOS Corporation, a BTG International group company, pioneered the development and clinical application of ultrasound infusion technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS™ EkoSonic™ Endovascular System to provide faster, safer and more complete dissolution of thrombus. To find out more about the EKOS™ EkoSonic™ Endovascular System, visit [www.ekoscorp.com](http://www.ekoscorp.com).

EKOS, the EKOS logo, Acoustic Pulse Thrombolysis, "Think Fast. Act Together", and EkoSonic are trademarks of Ekos Corporation, a BTG International group company. "Imagine where we can go.", BTG and the BTG roundel logo are trademarks of BTG International Ltd. EKOS, the EKOS logo, BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories.

All rights reserved. © 2018 EKOS Corporation. NA-EKO-2017-0464(1)

### About BTG

BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases.

The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.

To find out more about the BTG International group companies and our products, visit [www.btgplc.com](http://www.btgplc.com).

FDA Clearance: The EkoSonic™ Endovascular System is indicated for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified solutions, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries.

CE Mark: The EkoSonic™ Endovascular System is intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25 mmHg) or echocardiographic evaluation.

EKOS is a registered trademark of EKOS Corporation, a BTG International group company. 'Imagine where we can go' is a trademark of BTG International, Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in US, EU, and certain other territories and trademarks of BTG International Ltd elsewhere. © 2018 BTG International Ltd. NA-EKO-2017-0464(1).

Imagine where we can go.



[btg-im.com](http://btg-im.com)